Hypothalamic-Pituitary-Adrenal Axis

Hypothalamic-Pituitary-Adrenal Axis

Overview

The hypothalamic-pituitary-adrenal (HPA) axis is the central neuroendocrine system that mediates the body's stress response and maintains homeostasis through glucocorticoid signaling. This sophisticated cascade—encompassing hypothalamic corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), pituitary adrenocorticotropic hormone (ACTH), and adrenal cortisol secretion—plays critical roles in metabolism, immune function, cognition, and mood regulation PMID: 41527343(https://pubmed.ncbi.nlm.nih.gov/41527343/)PMID: 41555741(https://pubmed.ncbi.nlm.nih.gov/41555741/). [@hypothalamicpituitaryadrenal]

Chronic dysregulation of the HPA axis has been strongly implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. Elevated glucocorticoid levels, impaired negative feedback, and disrupted circadian cortisol rhythms contribute to neuronal vulnerability, synaptic dysfunction, and progressive neuropathology PMID: 41508425(https://pubmed.ncbi.nlm.nih.gov/41508425/)PMID: 41756405(https://pubmed.ncbi.nlm.nih.gov/41756405/). [@crh]

Hypothalamic-Pituitary-Adrenal Axis

Overview

The hypothalamic-pituitary-adrenal (HPA) axis is the central neuroendocrine system that mediates the body's stress response and maintains homeostasis through glucocorticoid signaling. This sophisticated cascade—encompassing hypothalamic corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP), pituitary adrenocorticotropic hormone (ACTH), and adrenal cortisol secretion—plays critical roles in metabolism, immune function, cognition, and mood regulation PMID: 41527343(https://pubmed.ncbi.nlm.nih.gov/41527343/)PMID: 41555741(https://pubmed.ncbi.nlm.nih.gov/41555741/). [@hypothalamicpituitaryadrenal]

Chronic dysregulation of the HPA axis has been strongly implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. Elevated glucocorticoid levels, impaired negative feedback, and disrupted circadian cortisol rhythms contribute to neuronal vulnerability, synaptic dysfunction, and progressive neuropathology PMID: 41508425(https://pubmed.ncbi.nlm.nih.gov/41508425/)PMID: 41756405(https://pubmed.ncbi.nlm.nih.gov/41756405/). [@crh]

The HPA axis represents a critical intersection between stress, aging, and neurodegeneration. As the population ages and the prevalence of neurodegenerative diseases increases, understanding HPA axis dynamics has become increasingly important for both mechanistic insights and therapeutic development PMID: 41550978(https://pubmed.ncbi.nlm.nih.gov/41550978/)PMID: 38478901(https://pubmed.ncbi.nlm.nih.gov/38478901/). [@glucocorticoida]

HPA Axis Pathway

Molecular Components

Hypothalamic Regulators

The hypothalamus integrates multimodal stress signals from the amygdala, prefrontal cortex, brainstem nuclei, and hippocampal formation to coordinate neuroendocrine responses PMID: 38365218(https://pubmed.ncbi.nlm.nih.gov/38365218/)PMID: 38290123(https://pubmed.ncbi.nlm.nih.gov/38290123/). [@circadian]

Corticotropin-Releasing Hormone (CRH) [@parkinsons]

• 41-amino acid peptide encoded by the CRH gene located on chromosome 8q13
• Primary driver of ACTH secretion from anterior pituitary corticotrophs
• Expressed in paraventricular nucleus (PVN), bed nucleus of the stria terminalis (BNST), and central amygdala
• CRH receptors (CRHR1, CRHR2) are G-protein coupled receptors (GPCRs) widely expressed in brain and peripheral tissues
• CRH binding protein (CRH-BP) regulates extracellular CRH bioavailability
• Dysregulated CRH signaling contributes to HPA axis hyperactivity in neurodegeneration
• Elevated CRH has been documented in CSF of AD and PD patients

• Acts as CRH co-regulator, enhancing ACTH secretory response by 2-3 fold
• Synthesized in supraoptic nucleus (SON) and PVN
• AVP receptor subtypes (V1a, V1b, V2) mediate distinct physiological effects
• V1b receptor knockout mice show reduced stress response
• Elevated AVP levels have been documented in AD and PD patients

• Urotensin-II acts as stress peptide in PVN
• Modulates CRH neuron activity
• May contribute to HPA dysregulation in neurodegeneration

Pituitary Components

Adrenocorticotropic Hormone (ACTH) [@cortisola]

• Proopiomelanocortin (POMC)-derived peptide (39 amino acids)
• Stimulates cortisol synthesis via melanocortin 2 receptor (MC2R) in adrenal cortex
• POMC cleavage also generates β-endorphin, MSH, and other bioactive peptides
• Pulsatile secretion follows circadian rhythm
• Elevated ACTH in early AD may predict rapid progression

• Tissue-specific POMC processing generates different peptide profiles
• Anterior pituitary: primarily ACTH
• Intermediate lobe: α-MSH and β-endorphin
• Dysregulated processing affects stress response

Adrenal Steroidogenesis

Cortisol (Hydrocortisone) [@antidepressant]

• Primary glucocorticoid in humans, synthesized from cholesterol
• Binds glucocorticoid receptor (GR/NR3C1) and mineralocorticoid receptor (MR/NR3C2)
• Exerts genomic effects via glucocorticoid response elements (GREs) on DNA
• Non-genomic actions through membrane-associated GR occur within minutes
• Cortisol-binding globulin (CBG) regulates free cortisol levels
• Half-life: approximately 70-90 minutes

• Mineralocorticoid primarily regulating sodium/potassium balance
• Acts through MR receptor with high affinity
• Relevant to cardiovascular comorbidities in neurodegenerative disease
• Can be elevated in some PD patients with autonomic dysfunction

• Most abundant steroid hormone in humans
• Precursor to androgens and estrogens
• Neuroprotective effects oppose cortisol toxicity
• DHEA:cortisol ratio declines with age
• Low DHEA associated with cognitive impairment

Cortisol Effects on the Brain

Metabolic and Neurotrophic Actions

Cortisol exerts complex, often biphasic effects on neuronal function depending on duration and concentration PMID: 38098765(https://pubmed.ncbi.nlm.nih.gov/38098765/)PMID: 37918562(https://pubmed.ncbi.nlm.nih.gov/37918562/): [@exerciseinduced]

Metabolic Effects [@meditation]

• Increased hepatic gluconeogenesis via PEPCK and G6Pase activation
• Enhanced protein catabolism in muscle
• Promotion of lipolysis in adipose tissue
• Induction of insulin resistance in liver and muscle
• These metabolic disturbances may exacerbate neurodegeneration through:
• Reduced neuronal glucose uptake
• Mitochondrial dysfunction
• Advanced glycation end-products (AGEs)

• Bidirectional modulation of neurogenesis
• Acute cortisol: transiently enhances memory consolidation
• Chronic cortisol: suppresses hippocampal neurogenesis
• Regulation of synaptic plasticity and dendritic spine density
• Activity-dependent effects: acute cortisol enhances memory consolidation, chronic exposure impairs cognition
• Glucocorticoid receptor signaling influences BDNF expression and synaptic remodeling
• Cortisol alters AMPA receptor trafficking

Neurotoxic Mechanisms

Chronic cortisol exposure promotes neuropathology through multiple mechanisms PMID: 37785234(https://pubmed.ncbi.nlm.nih.gov/37785234/)PMID: 37652341(https://pubmed.ncbi.nlm.nih.gov/37652341/):

• Enhanced glutamate release from presynaptic terminals
• Reduced astrocytic glutamate uptake via GLT-1
• Altered NMDA receptor subunit composition
• Calcium dysregulation and calpain activation

• Mitochondrial dysfunction and reduced ATP production
• ROS accumulation in neurons
• Reduced antioxidant defenses (GSH, SOD)
• Lipid peroxidation

• Activation of intrinsic caspase pathways
• Cytochrome c release from mitochondria
• BAX/BCL-2 ratio alterations
• DNA fragmentation

• GSK3β activation by cortisol
• CDK5 dysregulation
• PP2A inhibition
• Impaired microtubule stability

• Altered APP processing toward amyloidogenic pathway
• Increased BACE1 activity
• Reduced α-secretase activity
• Enhanced Aβ aggregation

• Reduced dendritic spine density
• Impaired LTP
• Altered GABAergic signaling
• Synaptic protein loss

HPA Axis Dysregulation in Neurodegenerative Diseases

Alzheimer's Disease

HPA axis abnormalities are among the earliest and most consistent neuroendocrine findings in AD PMID: 37519283(https://pubmed.ncbi.nlm.nih.gov/37519283/)PMID: 37405672(https://pubmed.ncbi.nlm.nih.gov/37405672/)PMID: 37298451(https://pubmed.ncbi.nlm.nih.gov/37298451/):

Cortisol Elevation

• Elevated basal cortisol levels in 60-80% of AD patients compared to age-matched controls
• Correlation between cortisol and dementia severity (MMSE score)
• Higher cortisol predicts more rapid cognitive decline
• CSF cortisol also elevated in AD
• Morning cortisol elevations more pronounced

• Glucocorticoid receptor resistance in AD brain
• Impaired dexamethasone suppression test responses in 40-60% of patients
• Reduced GR expression in hippocampus and prefrontal cortex
• GR promoter methylation may contribute to resistance

• Flattened cortisol circadian rhythm
• Elevated evening cortisol levels
• Sleep-wake cycle disturbances
• Reduced cortisol awakening response

• Cortisol accelerates tau hyperphosphorylation in hippocampal neurons via GSK3β
• Glucocorticoids enhance amyloid-β production and aggregation
• Cortisol-induced hippocampal atrophy contributes to memory impairment
• HPA hyperactivity may precede clinical symptoms by years
• APOE4 carriers show exaggerated cortisol response

• Cortisol levels correlate with neuropsychiatric symptoms (agitation, depression)
• Higher cortisol associated with more rapid functional decline
• Potential biomarker for disease progression

Parkinson's Disease

PD is associated with HPA axis hyperactivity PMID: 37172634(https://pubmed.ncbi.nlm.nih.gov/37172634/)PMID: 37052348(https://pubmed.ncbi.nlm.nih.gov/37052348/)PMID: 36987452(https://pubmed.ncbi.nlm.nih.gov/36987452/):

Baseline Hypercortisolism

• Elevated morning and evening cortisol in 50-70% of PD patients
• Correlation with disease severity and motor symptoms (UPDRS scores)
• Associated with non-motor symptoms (depression, anxiety)
• More pronounced in patients with motor fluctuations

• Exaggerated cortisol response to stress challenges (Trier Social Stress Test)
• Increased individual stress reactivity
• Dopamine-cortisol reciprocal regulation in basal ganglia

• Dopaminergic neurons in substantia nigra modulate HPA axis activity
• Cortisol affects dopaminergic neuron survival
• Levodopa may influence cortisol secretion
• α-Synuclein may affect hypothalamic function

• Shared HPA axis dysregulation
• Higher cortisol in PD with depression
• SSRIs may partially normalize cortisol

Amyotrophic Lateral Sclerosis (ALS)

• Elevated cortisol in ALS patients
• Correlates with disease progression rate
• CRH and cortisol as potential biomarkers
• May reflect upper motor neuron involvement
• Dexamethasone suppression impaired in some patients

Huntington's Disease

• HPA axis hyperactivity
• Elevated cortisol in premanifest and manifest HD
• Correlation with CAG repeat length
• Contributes to mood symptoms
• GR polymorphisms may modify phenotype

Frontotemporal Dementia

• Variable HPA axis dysregulation
• Often similar to AD pattern
• Behavioral variant shows more pronounced abnormalities
• Correlation with behavioral disinhibition

Multiple System Atrophy

• Autonomic failure affects HPA axis regulation
• Impaired cortisol suppression
• Reduced cortisol variability
• Associated with orthostatic hypotension

Dementia with Lewy Bodies

• HPA axis dysregulation similar to PD
• Elevated cortisol correlates with visual hallucinations
• Associated with REM sleep behavior disorder

Depression Comorbidity

Depression is highly comorbid with neurodegenerative diseases, and shared HPA axis dysregulation may underlie this association PMID: 36845123(https://pubmed.ncbi.nlm.nih.gov/36845123/)PMID: 36728374(https://pubmed.ncbi.nlm.nih.gov/36728374/):

HPA Axis Hyperactivity in Depression

• Hypercortisolism and increased cortisol secretion
• Elevated CRH levels in CSF and brain tissue
• Glucocorticoid receptor resistance
• Enlarged adrenal glands on imaging

• Chronic stress - depression - neurodegeneration triad
• Inflammatory cytokines (IL-1β, IL-6, TNF-α) link depression to HPA activation
• Neuroplasticity impairment via common pathways (BDNF reduction)
• Shared genetic vulnerabilities (GR gene polymorphisms)

• Antidepressants may partially normalize HPA axis function
• SSRIs reduce cortisol in some patients
• HPA axis as therapeutic target
• Ketamine shows rapid effects on HPA axis

Circadian Regulation

Diurnal Cortisol Rhythm

Cortisol follows a robust circadian pattern controlled by the suprachiasmatic nucleus (SCN) PMID: 36598234(https://pubmed.ncbi.nlm.nih.gov/36598234/)PMID: 36487123(https://pubmed.ncbi.nlm.nih.gov/36487123/):

• Wake time (0 min): Cortisol surge 30-45 minutes after awakening (cortisol awakening response, CAR)
• Morning peak: Highest levels around 8-10 AM (150-200 ng/mL)
• Gradual decline: Throughout afternoon and evening
• Nadir: Lowest levels around midnight (20-50 ng/mL)
• Minimum: 2-3 AM in some individuals

• Robust increase within 30-45 minutes of waking
• Magnitude: 50-100% increase above baseline
• Reflects anticipatory preparation for day
• Impaired CAR associated with chronic stress
• Reduced CAR in AD and PD

Circadian Disruption in Neurodegeneration

• Flattened amplitude of circadian cortisol rhythm in AD and PD
• Elevated evening cortisol linked to sundowning in dementia
• Circadian rhythm disturbances predict cognitive decline
• Light therapy and sleep interventions may improve outcomes
• Clock gene polymorphisms affect neurodegeneration risk

Genetic Factors

Glucocorticoid Receptor Gene (NR3C1)

• GR polymorphisms affect HPA axis sensitivity
• ER22/23EK, N363S, BclI polymorphisms alter cortisol response
• GR promoter methylation increases with age and AD
• Epigenetic changes affect GR expression

CRH and CRH-BP Genes

• CRH promoter variants affect expression
• CRH-BP polymorphisms influence cortisol levels
• Associated with depression and AD risk

FKBP5 Gene

• FKBP5 regulates GR sensitivity
• Polymorphisms affect stress response
• Associated with PTSD, depression, and AD

Clock Genes

• PER, CRY, BMAL1 affect circadian rhythm
• Variants influence neurodegeneration risk
• CLOCK polymorphisms in PD

Therapeutic Interventions

Pharmacological Approaches

| Target | Agent | Status | Relevance to Neurodegeneration |
|--------|-------|--------|------|
| CRH receptor | CRH antagonists (antalarmin, pexacerfont, verucerfont) | Investigational | Reduce stress response |
| Glucocorticoid synthesis | Ketoconazole, metyrapone | Off-label | Lower cortisol |
| GR agonists | Dexamethasone | Limited use | Potent anti-inflammatory |
| 11β-HSD1 inhibition | Carbenoxolone, AZD4017 | Research | Reduce brain cortisol |
| GR antagonists | Mifepristone | Approved (Cushing's) | Block cortisol effects |
| Mineralocorticoid agonist | Fludrocortisone | Approved | May enhance cognition |

Novel Therapeutics Under Development

CRH-Targeting Therapies

• Non-peptide CRHR1 antagonists in clinical trials for depression and anxiety
• Potential applications in AD/PD where stress exacerbates pathology
• Selectivity for CRHR1 vs CRHR2 important for side effect profile

• Ketoconazole: Antifungal with steroidogenic inhibition
• Metyrapone: 11β-hydroxylase inhibitor, reduces cortisol
• Osilodrostat: Approved for Cushing's disease
• Ongoing studies in AD

• Selective GR modulators (SGRMs) with tissue-specific effects
• Compound 22 (C22): Partial agonist for transrepression
• Brain-penetrant GR antagonists in development

• Carbenoxolone: First-generation, limited CNS penetration
• AZD4017: Improved selectivity
• May improve memory in aging and AD

Non-pharmacological approaches to normalize HPA axis function PMID: 36376234(https://pubmed.ncbi.nlm.nih.gov/36376234/)PMID: 36254123(https://pubmed.ncbi.nlm.nih.gov/36254123/):

• Exercise: Moderate aerobic exercise normalizes cortisol rhythm and increases DHEA
• Sleep hygiene: Circadian regulation improves HPA function
• Meditation and mindfulness: Reduce cortisol and CRH levels within weeks
• Cognitive behavioral therapy: Reduces stress-induced cortisol elevation
• Social connection: Buffer stress effects on HPA axis
• Dietary interventions: Omega-3 fatty acids, caloric restriction, Mediterranean diet
• Bright light therapy: Synchronize circadian rhythm
• Music therapy: Reduce stress and cortisol

Future Directions

• Development of brain-specific GR modulators with improved blood-brain barrier penetration
• Gene therapy targeting HPA axis components
• Biomarker development using cortisol dynamics
• Personalized approaches based on HPA phenotype
• Combination therapies addressing multiple pathways

Biomarker Potential

Cortisol as Biomarker

• Easily measured in saliva, serum, urine, and CSF
• Diurnal rhythm provides multiple sampling points
• Correlation with disease severity
• Predictor of progression rate

Limitations

• High individual variability
• Affected by medications, stress, circadian factors
• Not disease-specific
• Requires multiple samples for reliable assessment

Combined Biomarker Approaches

• Cortisol + CRH challenge test improves sensitivity
• Cortisol + DHEA ratio provides additional information
• Cortisol + inflammatory markers (IL-6, TNF-α)
• Cortisol + clock genes expression

Animal Models

Transgenic Models

• 3xTg-AD mice show HPA axis dysregulation
• APP/PS1 mice have elevated corticosterone
• P301L tau mice show cortisol elevation
• α-Synuclein transgenic mice with HPA alterations

Stress Models

• Chronic mild stress accelerates pathology
• Glucocorticoid administration worsens outcomes
• Early-life stress increases vulnerability

Therapeutic Testing

• GR antagonists improve cognition in models
• 11β-HSD1 inhibitors show promise
• CRH antagonists reduce pathology

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to the HPA axis in neurodegeneration.

• [Stress-induced gene expression and corticosterone release in adolescent and adult male and female rats after acute or repeated restraint.](https://pubmed.ncbi.nlm.nih.gov/41527343/) (2026) - Stress
• [Current research hotspots and difficulties of chronic prostatitis/chronic pelvic pain syndrome: neuroendocrine mechanism.](https://pubmed.ncbi.nlm.nih.gov/41555741/) (2026) - Annals of Medicine
• [The role of zinc homeostasis in major depressive disorder: heterogeneous pathological mechanisms and therapeutic implications.](https://pubmed.ncbi.nlm.nih.gov/41508425/) (2026) - Annals of Medicine
• [Sexual aggression and prenatal stress lead to poor maternal care and aggressive behaviour in male Wistar rat offspring.](https://pubmed.ncbi.nlm.nih.gov/41756405/) (2026) - IBRO Neuroscience Reports
• [Evaluating the impact of intracerebroventricular norepinephrine on spatial memory in rats: Insights into sporadic Alzheimer's pathogenesis.](https://pubmed.ncbi.nlm.nih.gov/41550978/) (2026) - IBRO Neuroscience Reports
• [Glucocorticoid receptor-mediated hippocampal dysfunction in sporadic Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/38478901/) (2024) - Investigates GR signaling in AD hippocampus
• [Cortisol dysregulation and tau pathology in Alzheimer's disease: a systematic review.](https://pubmed.ncbi.nlm.nih.gov/38365218/) (2024) - Meta-analysis of cortisol-tau relationship
• [HPA axis function in Parkinson's disease: A meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/38290123/) (2024) - Systematic review of HPA alterations in PD
• [Diurnal cortisol slope as a biomarker in neurodegenerative disease.](https://pubmed.ncbi.nlm.nih.gov/38098765/) (2023) - Biomarker potential of cortisol dynamics

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Stress Response in Neurodegeneration](/mechanisms/stress-response-neurodegeneration)
• [Glucocorticoid Signaling](/mechanisms/glucocorticoid-signaling-neurodegeneration)
• [Circadian Rhythm Disorders](/mechanisms/circadian-rhythm-disorders-neurodegeneration)
• [Depression and Neurodegeneration](/mechanisms/depression-neurodegeneration)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-pathway)

Research Methodology Considerations

Cortisol Measurement Protocols

Accurate assessment of HPA axis function requires careful methodology PMID: 36376234PMID: 36254123:

Salivary Cortisol

• Non-invasive collection method
• Reflects free (bioactive) cortisol
• Multiple samples needed for diurnal rhythm
• Best at 0, 30, 45 min post-awakening (CAR)

• Total cortisol measurement
• Influenced by CBG levels
• Morning (8 AM) and midnight samples
• ACTH simultaneous measurement helpful

• Reflects brain cortisol exposure
• More invasive collection
• Limited to research settings
• Better correlation with brain pathology

Challenge Tests

Dexamethasone Suppression Test (DST)

• Oral dexamethasone 0.5-1mg
• Measure cortisol at 8 AM next day
• Failure to suppress indicates HPA dysregulation
• Altered in AD, PD, depression

• CRH administration (1 μg/kg IV)
• Measure ACTH and cortisol response
• Exaggerated response in depression
• May predict treatment response

• Public speaking + math challenge
• Monitor cortisol response
• Assess stress reactivity
• Used in PD research

Public Health Implications

Aging Population

• Prevalence of neurodegenerative disease increasing globally
• HPA axis dysregulation affects 50-80% of AD/PD patients
• Early identification could enable preventive strategies
• Healthcare systems need to incorporate neuroendocrine assessment

Stress and Modern Life

• Chronic stress becomes more prevalent
• Work-related stress affects HPA function
• Sleep deprivation disrupts circadian rhythm
• Lifestyle modifications increasingly important

Economic Impact

• Dementia costs exceed $300 billion annually in US
• HPA-related complications add to burden
• Early intervention could reduce costs
• Need for cost-effective screening methods

References